ERBB2 and neoplasm: Beyond this, the high intraobserver variability, as shown in the VARIANZ study, especially in tumours with intermediate HER2 expression, demonstrates how interpreting HER2 amplification results can be challenging for pathologists requiring training and expertise [27].